E7386-J081-102_(PENT-02)

**Study Summary**;E7386-J081-102 is an open-label, phase 1b/2 trial of the investigational tankyrase inhibitor E7386, given in combination with other anticancer agents (notably lenvatinib, E7080), in patients with advanced or unresectable solid tumors. The study is conducted across approximately 80 experimental sites worldwide over a planned duration of \~76 months (main analysis) and comprises three partsÀdose escalation, expansion (in hepatocellular carcinoma, colorectal cancer and endometrial carcinoma), and dose optimization in endometrial carcinoma .;**Primary Objectives**;* **Safety and tolerability & RP2D determination:** Evaluate the safety profile and tolerability of E7386 in combination with other anticancer drugs and identify the recommended phase 2 dose (RP2D) for subsequent evaluation.;* **Endometrial carcinoma dose optimization:** Determine the optimal dose of E7386 when combined with lenvatinib specifically in patients with endometrial carcinoma .